title: Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia.
abstract: Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go on to have chronic ITP. In those children with chronic ITP who need treatment, standard therapies for acute ITP may have adverse effects that complicate their long-term use. Thus, alternative treatment options are needed for children with chronic ITP. Thrombopoietin receptor agonists (TPO-RA) have been shown to be safe and efficacious in adults with ITP, and represent a new treatment option for children with chronic ITP. One TPO-RA, eltrombopag, is now approved for children. Clinical trials in children are ongoing and data are emerging on safety and efficacy. This review will focus on the physiology of TPO-RA, their clinical use in children, as well as the long-term safety issues that need to be considered when using these agents.
authors: Department of Pediatrics, Memorial Sloan Kettering Cancer Center , New York, NY , USA.
authors: Angelica Maria
authors: AM
authors: Garzon
authors: Laboratory of Platelet Biology, New York Blood Center , New York, NY , USA ; Division of Pediatric Hematology Oncology, Weill Cornell Medical College , New York, NY , USA.
authors: William Beau
authors: WB
authors: Mitchell
keywords: chronic immune thrombocytopenia; eltrombopag; immune thrombocytopenia; romiplostim; thrombopoietin receptor agonists